A mini-review of TAT-MyoD fused proteins: state of the art and problems to solve

CCAAT/Enhancer-Binding Protein ε27 Antagonism of GATA-1 Transcriptional Activity in the Eosinophil Is Mediated by a Unique N-Terminal Repression Domain, Is Independent of Sumoylation and Does Not Require DNA Binding

CCAAT/enhancer binding protein epsilon (C/EBPε) is required for eosinophil differentiation, lineage-specific gene transcription, and expression of C/EBPε³² and shorter 27kD and 14kD isoforms is developmentally regulated during this process. We previously defined the 27kD isoform (C/EBPε²⁷) as an antagonist of GATA-1 transactivation of the eosinophil's major basic protein-1 (MBP1) P2-promoter, showing C/EBPε²⁷ and GATA-1 physically interact. In the current study, we used a Tat-C/EBPε²⁷ fusion protein for cell/nuclear transduction of an eosinophil myelocyte cell line to demonstrate that C/EBPε²⁷ is a potent repressor of MBP1 transcription. We performed structure-function analyses of C/EBPε²⁷ mapping its repressor domains, comparing it to C/EBPε³² and C/EBPε¹⁴, using GATA-1 co-transactivation of the MBP1-P2 promoter. Results show C/EBPε²⁷ repression of GATA-1 is mediated by its unique 68aa N-terminus combined with previously identified RDI domain. This repressor activity does not require, but is enhanced by, DNA binding via the basic region of C/EBPε²⁷ but independent of sumoylation of the RDI core "VKEEP" sumoylation site. These findings identify the N-terminus of C/EBPε²⁷ as the minimum repressor domain required for antagonism of GATA-1 in the eosinophil. C/EBPε²⁷ repression of GATA-1 occurs via a combination of both C/EBPε²⁷-GATA-1 protein-protein interaction and C/EBPε²⁷ binding to a C/EBP site in the MBP1 promoter. The C/EBPε²⁷ isoform may serve to titrate and/or turn off eosinophil granule protein genes like MBP1 during eosinophil differentiation, as these genes are ultimately silenced in the mature cell. Understanding the functionality of C/EBPε²⁷ in eosinophil development may prove promising in developing therapeutics that reduce eosinophil proliferation in allergic diseases.

EJTM3 is also covering Mobility and Medicine at large, an update

Since the first 2018 issue, the European Journal of Translational Myology expanded its authorship and readership from the strict topics of biology, physiology, diagnostic, management and rehabilitation of skeletal muscle to the more clinically relevant fields of human mobility to those of general medicine. This third issue opens with a review on Chronic Fatigue Syndrome, a very complex medical problem, as its other names testify (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease). A more typical molecular myology original article follows (Increasing autophagy does not affect neurogenic muscle atrophy), but then several Rapid Reports cover different Medical Specialties fields, related or unrelated to neuromyology, mobility problems and their potential solutions. The Advisors of EJTM invite Authors to submit typescripts, taking into account that the journal is keen to publish high-level papers in the fields of Translational Myology, Mobility and Medicine at large.